GlassScriptPhysician profile
Kenneth D Calhoun
NPI 1225093222
$5,975.96
in general payments reported to CMS, 2019-2025
32 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,451 · 2020: $475 · 2021: $1,054 · 2022: $217 · 2023: $523 · 2024: $636 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $886.45 | 2019-2025 | |
| Novo Nordisk INC | $805.57 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $707.30 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $478.89 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.84 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $344.76 | 2021 | |
| Abbvie INC. | $278.01 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.21 | 2019-2020 | |
| Amgen INC. | $183.04 | 2019-2020 | |
| Amarin Pharma, INC. | $179.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $139.97 | 2019 | |
| Organogenesis INC. | $137.38 | 2019-2020 | |
| Integra Lifesciences Corporation | $132.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $122.76 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $119.70 | 2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $117.50 | 2022 | |
| Axsome Therapeutics, INC. | $94.50 | 2025 | Auvelity |
| Lilly USA, LLC | $87.70 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.61 | 2019 | |
| Exact Sciences Corporation | $61.07 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $58.79 | 2019-2020 | |
| Kerecis Limited | $44.61 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Supernus Pharmaceuticals, INC. | $43.21 | 2019 | |
| Zyla Life Sciences, INC. | $40.51 | 2019 | |
| Astellas Pharma US INC | $35.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.23 | 2020 | |
| Melinta Therapeutics, LLC | $27.89 | 2019 | |
| Genentech USA, INC. | $25.58 | 2020 | |
| Merck Sharp & Dohme LLC | $24.77 | 2019 | |
| Polynovo North America LLC | $14.67 | 2024 | Novosorb Btm |
| Flowonix Medical Incorporated | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.